![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ZIM3 |
Gene summary for ZIM3 |
![]() |
Gene information | Species | Human | Gene symbol | ZIM3 | Gene ID | 114026 |
Gene name | zinc finger imprinted 3 | |
Gene Alias | ZNF264 | |
Cytomap | 19q13.43 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q96PE6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
114026 | ZIM3 | HCC1 | Human | Liver | HCC | 1.08e-05 | 5.88e-01 | 0.5336 |
114026 | ZIM3 | HCC2 | Human | Liver | HCC | 4.05e-12 | 9.81e-01 | 0.5341 |
114026 | ZIM3 | HCC5 | Human | Liver | HCC | 3.09e-02 | 6.24e-01 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZIM3 | SNV | Missense_Mutation | novel | c.855N>T | p.Glu285Asp | p.E285D | Q96PE6 | protein_coding | deleterious(0.01) | possibly_damaging(0.566) | TCGA-EY-A1GI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZIM3 | SNV | Missense_Mutation | novel | c.749N>T | p.Pro250Leu | p.P250L | Q96PE6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EY-A1GI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZIM3 | insertion | Frame_Shift_Ins | rs750173990 | c.1150dupA | p.Ile384AsnfsTer9 | p.I384Nfs*9 | Q96PE6 | protein_coding | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD | ||
ZIM3 | deletion | Frame_Shift_Del | c.897delA | p.Val300PhefsTer24 | p.V300Ffs*24 | Q96PE6 | protein_coding | TCGA-D1-A1NZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |||
ZIM3 | SNV | Missense_Mutation | c.382C>T | p.Pro128Ser | p.P128S | Q96PE6 | protein_coding | tolerated(0.67) | benign(0.024) | TCGA-CC-A7IL-01 | Liver | liver hepatocellular carcinoma | Male | <65 | III/IV | Unknown | Unknown | PD | |
ZIM3 | SNV | Missense_Mutation | novel | c.170T>C | p.Val57Ala | p.V57A | Q96PE6 | protein_coding | tolerated(0.1) | benign(0.176) | TCGA-DD-AAEA-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ZIM3 | SNV | Missense_Mutation | c.794N>G | p.Ser265Cys | p.S265C | Q96PE6 | protein_coding | tolerated(0.13) | benign(0.007) | TCGA-FV-A3I0-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Chemotherapy | gemcitabine | PD | |
ZIM3 | SNV | Missense_Mutation | novel | c.1264N>G | p.Ser422Gly | p.S422G | Q96PE6 | protein_coding | tolerated(0.08) | benign(0.215) | TCGA-WJ-A86L-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZIM3 | SNV | Missense_Mutation | c.148N>A | p.Gly50Arg | p.G50R | Q96PE6 | protein_coding | tolerated(0.54) | benign(0) | TCGA-44-3918-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD | |
ZIM3 | SNV | Missense_Mutation | c.886C>A | p.Gln296Lys | p.Q296K | Q96PE6 | protein_coding | tolerated(0.91) | benign(0.089) | TCGA-44-6144-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |